Collegium Pharmaceutical (NASDAQ:COLL) had its price objective increased by stock analysts at Jefferies Group to $27.00 in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s target price points to a potential upside of 56.89% from the stock’s previous close. Jefferies Group also issued estimates for Collegium Pharmaceutical’s FY2021 earnings at $1.36 EPS.

A number of other analysts have also issued reports on the stock. Piper Jaffray Companies set a $19.00 price objective on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, November 29th. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, November 17th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Monday, November 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $22.67.

Collegium Pharmaceutical (NASDAQ COLL) opened at $17.21 on Tuesday. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $20.92.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.28. The firm had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. Collegium Pharmaceutical’s revenue was up 2814.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.13) earnings per share. research analysts forecast that Collegium Pharmaceutical will post -2.56 earnings per share for the current year.

In related news, CEO Michael Thomas Heffernan sold 50,000 shares of Collegium Pharmaceutical stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total value of $776,500.00. Following the completion of the sale, the chief executive officer now owns 558,987 shares in the company, valued at $8,681,068.11. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Alison B. Fleming sold 4,601 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the sale, the insider now owns 28,513 shares of the company’s stock, valued at approximately $491,849.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,630 shares of company stock valued at $924,360. Insiders own 25.76% of the company’s stock.

Large investors have recently modified their holdings of the stock. American International Group Inc. increased its stake in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares during the last quarter. Voya Investment Management LLC bought a new stake in shares of Collegium Pharmaceutical in the second quarter worth $125,000. Nationwide Fund Advisors increased its stake in shares of Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after buying an additional 2,802 shares during the last quarter. Credit Suisse AG increased its stake in shares of Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares during the last quarter. Finally, UBS Group AG increased its stake in shares of Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 10,174 shares during the last quarter. Institutional investors and hedge funds own 79.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Jefferies Group Increases Collegium Pharmaceutical (COLL) Price Target to $27.00” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2017/12/07/jefferies-group-increases-collegium-pharmaceutical-coll-price-target-to-27-00.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.